A researcher at Tel Aviv University's Sackler School of Medicine has developed what could be a new weight-loss wonder drug, which not only quells the desire to consume fatty foods, but also has fewer side effects.
Dr. Nir Barak developed the drug in conjunction with the drug company Obecure.
Diet Pills
Diet pills are flooding the market by millions. The positive side of diet pills to most people is that they achieve their objective of losing weight. Medical reviews are against the use of diet pills.
Advertisement
The drug, called HistaleanTM, is based on betahistine, an approved drug used for the treatment of vertigo.
It is believed that Betahistine works by blocking H1 and H3 receptors in the brain that are linked to one's sense of feeling full and the desire to eat fatty foods.
![‘NEAT-O’ Results Expected From Weight Loss Game]( "‘NEAT-O’ Results Expected From Weight Loss Game")
The professor is meeting the weighty challenge of a billion overweight people in the world with a challenge of his own by finding a way to motivate the people in the
The pill, Histalean, also suppresses the desire to consume fatty foods, and the effects have been more prominent in women.
"Our new results suggest a strong gender-and-age-effect and support the potential of the drug as a breakthrough anti-obesity agent in women 50 years old or less," Dr. Yaffa Beck, Obecure's CEO said.
With the help of a recent Phase II clinical trial of the new drug in the U.S., in which 281 patients between the age group 18-65 years were studied, it was suggested that women under the age of 50 who took Histalean for 12 weeks lost 7 times the weight of those taking a placebo.
Moreover, none of the patients complained of any serious side effects. U.S. weight-loss guru Dr. Robert Kushner who supervised the trial said: "The women who took the pill reported 'It wasn't hard. I wasn't thinking about food. I was content.'"
The subgroup of women who were treated with a high-dose Histalean lost an average of 2.91pct of their weight whereas women in the placebo group lost only 0.4 pct.
Dr. Barak explained since the new drug has already been proved safe it will be a massive hit because all the other drugs in the diet pill market have serious side effects.
Source: ANI
LIN /J
‘NEAT-O’ Results Expected From Weight Loss Game
The professor is meeting the weighty challenge of a billion overweight people in the world with a challenge of his own by finding a way to motivate the people in the
Advertisement
The pill, Histalean, also suppresses the desire to consume fatty foods, and the effects have been more prominent in women.
"Our new results suggest a strong gender-and-age-effect and support the potential of the drug as a breakthrough anti-obesity agent in women 50 years old or less," Dr. Yaffa Beck, Obecure's CEO said.
With the help of a recent Phase II clinical trial of the new drug in the U.S., in which 281 patients between the age group 18-65 years were studied, it was suggested that women under the age of 50 who took Histalean for 12 weeks lost 7 times the weight of those taking a placebo.
Moreover, none of the patients complained of any serious side effects. U.S. weight-loss guru Dr. Robert Kushner who supervised the trial said: "The women who took the pill reported 'It wasn't hard. I wasn't thinking about food. I was content.'"
The subgroup of women who were treated with a high-dose Histalean lost an average of 2.91pct of their weight whereas women in the placebo group lost only 0.4 pct.
Dr. Barak explained since the new drug has already been proved safe it will be a massive hit because all the other drugs in the diet pill market have serious side effects.
Source: ANI
LIN /J
Advertisement
Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
